# US 2016/0250249 A1 · Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250249 A1
- Document ID: US20160250249A1
- Status: Published application
- Kind: A1
- Application number: 15/026,986
- Filed: 2014-10-03
- Published: 2016-09-01
- Earliest claimed: 2013-10-03
- Assignees: Inserm ( Institute National De Lasanté Et De La Re Cherche MéDicale)
- Applicants: Inserm ( Institute National De Lasanté Et De La Re Cherche MéDicale); Assistance Publique-Hopitaux De Paris (Aphp); Universite Paris Descartes; Universite Pierre Et Marie Curie (Paris 6); Universite Paris Diderot - Paris 7; Universite Paris-Sud; Institut Gustave Roussy
- Inventors: Guido KROEMER; Guillermo MARINO; Federico PIETROCOLA
- Web page: https://patentgrep.com/patent/US20160250249A1

## CPC

- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/225: Polycarboxylic acids
- A61K 31/235: having an aromatic ring attached to a carboxyl group
- A61K 31/385: having two or more sulfur atoms in the same ring
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/4458: only substituted in position 2, e.g. methylphenidate
- A61K 31/7008: Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides novel methods for the modulation of autophagy and the treatment of autophagy-related diseases, including cancer, neurodegenerative diseases, liver diseases, muscle diseases and pancreatitis.

## Claims

### Claim 1

A method of inducing autophagy in a subject comprising administering the subject with an amount of at least one AcCoA depleting agent.

### Claim 2 (depends on 1)

The method of claim 1 wherein the subject suffers from a disease selected from the group consisting of cancer diseases, neurodegenerative diseases, cardiovascular diseases such as ischemia, infectious diseases, auto-immune disease and/or inflammatory diseases such as pancreatitis, proteinopathies, metabolic diseases such as obesity and insulin resistance.

### Claim 3 (depends on 1)

The method of claim 1 wherein the AcCoA depleting agent is selected from the group consisting of inhibitors of inhibitors of the glycolytic or lipolytic pathways, inhibitors of the mitochondrial export of AcCoA, or inhibitors of cytosolic AcCoA synthase.

### Claim 4 (depends on 1)

The method of claim 1 wherein the AcCoA depleting agent is an inhibitor of mitochondrial pyruvate carrier complex (MPC) such as UK5099 (2-Cyano-3-(1-phenyl-1H-indol-3-yl)-2-propenoic acid).

### Claim 5 (depends on 1)

The method of claim 1 wherein the AcCoA depleting agent is an inhibitor of mitochondrial carnitine palmitoytransferase-1 (CTP1) such as perhexiline (PHX) or an inhibitor of CTP1c expression.

### Claim 6 (depends on 1)

The method of claim 1 wherein the AcCoA depleting agent is an inhibitor of mitochondrial citrate carrier (CiC), such as benzenetricarboxylate (BTC).

### Claim 7 (depends on 1)

The method of claim 1 wherein the AcCoA depleting agent is an inhibitor of ATP-citratre lyase (ACLY) such as hydroxycitrate, (R,S)—S-(3,4-dicarboxy-3-hydroxy-3-methyl-butyl)-CoA, and S-carboxymethyl-CoA.

### Claim 8 (depends on 1)

The method of claim 1 wherein the AcCoA depleting agent is an EP300 acetyltransferase inhibitor such as aspirin, acetylate derivatives and C646.

### Claim 9 (depends on 1)

The method of claim 1 wherein the AcCoA depleting agent is an inhibitor of acyl-CoA synthetase short-chain family member 2 (ACCS2).

### Claim 10

A method of inhibiting autophagy in a subject comprising administering the subject with a therapeutically effective amount AcCoA and/or at least one AcCoA replenishing agent.

### Claim 11 (depends on 10)

The method of claim 10 wherein the subject suffers from a disease selected from the group consisting of cardiovascular diseases such as surgical thoracic constriction (TAC), infectious diseases such as bacterial infections, cancer such as cancer with an advanced stage (stage II or IV), pulmonary diseases such as chronic obstructive pulmonary disease (COPD), hepatic diseases such as liver fibrosis, lysosomal impairment diseases, such as Danon disease, X-linked myopathy with excessive autophagy (XMEA), Glycogen Storage Type II (GSDII), Pompe disease, muscular diseases such as muscular atrophy.

### Claim 12 (depends on 10)

The method of claim 10 wherein the AcCoA-replenishing agent is selected from the group consisting of dicholoroacetate (DCA), lipoic acid (LA), ketoisocaproic acid (KIC), butyrate and dimethy-α-ketoglutarate (DMKG).

### Claim 13

A method for treating a cancer in a subject in need thereof comprising administering the subject with a therapeutically effective amount of AcCoA depleting agent and a therapeutically effective amount of a chemotherapeutic agent wherein the AcCoA depleting agent is administered prior to the chemotherapeutic agent.

### Claim 14 (depends on 13)

The method of claim 13 wherein the AcCoA depleting agent is administered 12; 13; 14; 15; 16; 17; 18; 19; 20; 21; 22; 23; 24; 25; 26; 27; 28; 29; 30; 31; 32; 33; 34; 35; 36; 37; 38; 39; 40; 41; 42; 43; 44; 45; 46; 47; 48; 49; 50; 51; 52; 53; 54; 55; or 56 h before the administration of the chemotherapeutic agent.

### Claim 15 (depends on 14)

The method of claim 14 wherein the cancer is selected from the group consisting of cancer cells from the bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, gastrointestine, gum, head, kidney, liver, lung, nasopharynx, neck, ovary, prostate, skin, stomach, testis, tongue, or uterus. In addition, the cancer may specifically be of the following histological type, though it is not limited to these: neoplasm, malignant; carcinoma; carcinoma, undifferentiated; giant and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphoepithelial carcinoma; basal cell carcinoma; pilomatrix carcinoma; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant; cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular carcinoma and cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma; adenocarcinoma in adenomatous polyp; adenocarcinoma, familial polyposis coli; solid carcinoma; carcinoid tumor, malignant; branchiolo-alveolar adenocarcinoma; papillary adenocarcinoma; chromophobe carcinoma; acidophil carcinoma; oxyphilic adenocarcinoma; basophil carcinoma; clear cell adenocarcinoma; granular cell carcinoma; follicular adenocarcinoma; papillary and follicular adenocarcinoma; nonencapsulating sclerosing carcinoma; adrenal cortical carcinoma; endometroid carcinoma; skin appendage carcinoma; apocrine adenocarcinoma; sebaceous adenocarcinoma; ceruminous; adenocarcinoma; mucoepidermoid carcinoma; cystadenocarcinoma; papillary cystadenocarcinoma; papillary serous cystadenocarcinoma; mucinous cystadenocarcinoma; mucinous adenocarcinoma; signet ring cell carcinoma; infiltrating duct carcinoma; medullary carcinoma; lobular carcinoma; inflammatory carcinoma; paget's disease, mammary; acinar cell carcinoma; adenosquamous carcinoma; adenocarcinoma w/squamous metaplasia; thymoma, malignant; ovarian stromal tumor, malignant; thecoma, malignant; granulosa cell tumor, malignant; and roblastoma, malignant; Sertoli cell carcinoma; leydig cell tumor, malignant; lipid cell tumor, malignant; paraganglioma, malignant; extra-mammary paraganglioma, malignant; pheochromocytoma; glomangiosarcoma; malignant melanoma; amelanotic melanoma; superficial spreading melanoma; malig melanoma in giant pigmented nevus; epithelioid cell melanoma; blue nevus, malignant; sarcoma; fibrosarcoma; fibrous histiocytoma, malignant; myxosarcoma; liposarcoma; leiomyosarcoma; rhabdomyosarcoma; embryonal rhabdomyosarcoma; alveolar rhabdomyo sarcoma; stromal sarcoma; mixed tumor, malignant; mullerian mixed tumor; nephroblastoma; hepatoblastoma; carcinosarcoma; mesenchymoma, malignant; brenner tumor, malignant; phyllodes tumor, malignant; synovial sarcoma; mesothelioma, malignant; dysgerminoma; embryonal carcinoma; teratoma, malignant; struma ovarii, malignant; choriocarcinoma; mesonephroma, malignant; hemangiosarcoma; hemangioendothelioma, malignant; kaposi's sarcoma; hemangiopericytoma, malignant; lymphangiosarcoma; osteosarcoma; juxtacortical osteosarcoma; chondrosarcoma; chondroblastoma, malignant; mesenchymal chondrosarcoma; giant cell tumor of bone; ewing's sarcoma; odontogenic tumor, malignant; ameloblastic odontosarcoma; ameloblastoma, malignant; ameloblastic fibrosarcoma; pinealoma, malignant; chordoma; glioma, malignant; ependymoma; astrocytoma; protoplasmic astrocytoma; fibrillary astrocytoma; astroblastoma; glioblastoma; oligodendroglioma; oligodendroblastoma; primitive neuroectodermal; cerebellar sarcoma; ganglioneuroblastoma; neuroblastoma; retinoblastoma; olfactory neurogenic tumor; meningioma, malignant; neurofibrosarcoma; neurilemmoma, malignant; granular cell tumor, malignant; malignant lymphoma; Hodgkin's disease; Hodgkin's lymphoma; paragranuloma; malignant lymphoma, small lymphocytic; malignant lymphoma, large cell, diffuse; malignant lymphoma, follicular; mycosis fungoides; other specified non-Hodgkin's lymphomas; malignant histiocytosis; multiple myeloma; mast cell sarcoma; immunoproliferative small intestinal disease; leukemia; lymphoid leukemia; plasma cell leukemia; erythroleukemia; lymphosarcoma cell leukemia; myeloid leukemia; basophilic leukemia; eosinophilic leukemia; monocytic leukemia; mast cell leukemia; megakaryoblastic leukemia; myeloid sarcoma; and hairy cell leukemia.

### Claim 16 (depends on 14)

The method of claim 14 wherein the cancer is KRAS mutated cancer.

### Claim 17 (depends on 13)

The method of claim 13 wherein the chemotherapeutic agent is selected from the group consisting of 1. alkylating agents such as thiotepa and cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as the enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gammall and calicheamicin omegall; dynemicin, including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores, aclacinomysins, actinomycin, authrarnycin, azaserine, bleomycins, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxy doxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK polysaccharide complex); razoxane; rhizoxin; sizofuran; spirogermanium; tenuazonic acid; triaziquone; 2,2′,2″-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside (“Ara-C”); cyclophosphamide; thiotepa; taxoids, e.g., paclitaxel and doxetaxel; chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum coordination complexes such as cisplatin, oxaliplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; irinotecan (e.g., CPT-1 1); topoisomerase inhibitor RFS 2000; difluoromethylomithine (DMFO); retinoids such as retinoic acid; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above.

### Claim 18

A kit-of-parts comprising at least one AcCoA depleting agent and at least one chemotherapeutic agent for use in the treatment of cancer.

### Claim 19

A method for screening a plurality of test substances useful for inducing autophagy in a cell comprising the steps of (a) testing each of the test substances for its ability to deplete AcCoA in the cell and b) positively selecting the test substances capable of depleting AcCoA in the cell.

### Claim 20 (depends on 19)

The method of claim 19 which further comprises the steps of (a) testing each of the test substances for its ability to inhibit the activity or expression of a autophagy-related gene product selected from the group consisting of mitochondrial pyruvate carrier complex, mitochondrial carnitine palmitoytransferase-1, mitochondrial citrate carrier (CiC), ATP-citratre lyase (ACLY), EP300 acetyltransferase, acyl-CoA synthetase short-chain family member 2 (ACCS2) and b) positively selecting the test substances capable of inhibiting the autophagy-related gene product.
